An amino acid composition for treating alopecia and use thereof in the manufacture of a medicament for treating alopecia

Abstract

The application discloses an amino acid composition for treating alopecia and application of the amino acid composition in preparation of a medicine for treating alopecia, and belongs to the field of medicine preparation, wherein the amino acid composition is composed of a targeted core intervention component and an auxiliary reinforcing synergistic component; the targeted core intervention component is composed of 30-50 parts of arginine, 50-155 parts of lysine, 50-120 parts of glutamic acid, 10-40 parts of cysteine and 20-60 parts of leucine; the auxiliary reinforcing synergistic component is composed of 15-45 parts of tyrosine, 15-40 parts of glycine, 10-40 parts of glutamine, 20-35 parts of serine, 5-25 parts of alanine, 2-20 parts of aspartic acid and 15-35 parts of phenylalanine; the amino acid composition can be prepared into different dosage forms such as a coating agent, a spray agent, a paste agent and a rubbing agent as active ingredients, and is applied to prevention of alopecia, promotion of hair growth and treatment, and the treatment effect is remarkable.

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical formulation technology, specifically relating to an amino acid composition for treating hair loss and its application in the preparation of a drug for treating hair loss. Background Technology

[0002] Hair loss is an increasingly prevalent health problem worldwide, and its epidemiological data has attracted widespread attention. Although hair loss itself does not directly threaten life, the limitations of existing treatments significantly restrict the fulfillment of clinical needs. The core mechanism of action of current mainstream hair regrowth drugs focuses on "reducing hair follicle death," that is, alleviating hair loss symptoms by delaying the hair follicle degeneration process, rather than directly activating hair follicle growth signaling pathways to achieve active hair growth promotion. More importantly, these drugs are generally accompanied by adverse reactions such as skin sensitivity, dizziness, and tachycardia, and their applicability in various scenarios and safety for long-term use have significant shortcomings. Therefore, developing safe, efficient, and fundamentally effective hair loss treatment technologies has become one of the core research directions in the current biomedical field.

[0003] Drug therapy, currently the most widely used clinical intervention for hair loss, focuses its research and development on two core objectives: "inhibiting hair follicle degeneration" and "activating hair follicle growth." Among these, vasodilators, represented by minoxidil, improve blood supply to hair follicles by dilating scalp capillaries, prolonging the hair follicle growth phase. Clinical studies show an efficacy rate of approximately 40%–60%, but long-term use is required (usually no less than 6 months), and hair loss relapse is common after discontinuation, limiting the stability of its long-term efficacy. Anti-androgen drugs, such as finasteride, reduce dihydrotestosterone (DHT) production by inhibiting 5α-reductase activity—a key factor in androgenetic alopecia. Lowering DHT levels can alleviate hair follicle atrophy; however, this drug is only suitable for male patients with androgenetic alopecia, and approximately 3% of users experience sexual dysfunction. The use of certain drugs, such as tofacitinib, is restricted due to its use in women and its explicit prohibition on female use, resulting in a significant limitation in the target population. Immunomodulatory drugs, such as tofacitinib, target immune-related alopecia areata by inhibiting the JAK-STAT signaling pathway to improve the local immune microenvironment of hair follicles. Phase II clinical trial data show that it can increase hair growth rate by 50%, but the safety of long-term use still needs further verification. Growth factor-targeting drugs, such as VEGF / FGF agonists, can directly activate hair follicle cell proliferation signals, but their development is still in the preclinical stage and faces technical bottlenecks such as low skin penetration efficiency and insufficient local targeting, and have not yet entered the clinical application stage.

[0004] Understanding the structure and metabolic mechanisms of hair is a fundamental prerequisite for developing hair loss treatment technologies. The main structural component of hair is keratin, a protein composed of various amino acids linked by peptide bonds to form a stable three-dimensional structure. Specific amino acids play an irreplaceable role in maintaining hair health. Although existing research has clarified the auxiliary value of amino acid supplementation in nutritional deficiency-related hair loss, its functional positioning is vague, its effects are scattered, synergistic effects are insufficiently studied, and it lacks systematic support. Furthermore, it faces multiple technical limitations in clinical translation, hindering its widespread application. Summary of the Invention

[0005] In view of the problems existing in the above and / or prior art, the present invention is proposed.

[0006] Therefore, the object of the present invention is to overcome the shortcomings of the prior art and provide an amino acid composition for treating hair loss.

[0007] To solve the above-mentioned technical problems, the present invention provides the following technical solution: the amino acid composition is composed of a targeting core intervention component and an auxiliary strengthening and synergistic component, wherein, by mass parts,

[0008] The targeted core intervention component consists of 30-50 parts arginine, 90-155 parts lysine, 100-120 parts glutamic acid, 25-40 parts cysteine, and 45-60 parts leucine.

[0009] The auxiliary strengthening and synergistic component consists of 30-45 parts tyrosine, 30-40 parts glycine, 20-40 parts glutamine, 28-35 parts serine, 15-25 parts alanine, 5-20 parts aspartic acid, and 25-35 parts phenylalanine.

[0010] In a preferred embodiment of the amino acid composition for treating hair loss according to the present invention, the mass ratio of the core intervention component to the auxiliary strengthening and synergistic component is 7~8:2~3.

[0011] In a preferred embodiment of the amino acid composition for treating hair loss according to the present invention, the mass ratio of arginine to lysine is 3:8~10.

[0012] As a preferred embodiment of the amino acid composition for treating hair loss according to the present invention, the targeted core intervention component is composed of 30-40 parts arginine, 90-120 parts lysine, 100-110 parts glutamic acid, 25-30 parts cysteine, and 45-50 parts leucine.

[0013] As a preferred embodiment of the amino acid composition for treating hair loss according to the present invention, the auxiliary strengthening and synergistic component is composed of 30-35 parts tyrosine, 30-34 parts glycine, 20-30 parts glutamine, 28-35 parts serine, 15-25 parts alanine, 5-20 parts aspartic acid, and 25-31 parts phenylalanine.

[0014] Another object of the present invention is to provide the use of an amino acid composition for treating hair loss in the preparation of a medicament for treating hair loss.

[0015] To solve the above-mentioned technical problems, the present invention provides the following technical solution: the drug for treating hair loss uses an amino acid composition for treating hair loss as the active ingredient, and also includes pharmaceutically acceptable adjuvants.

[0016] It should be noted that when using an amino acid composition for treating hair loss as the active ingredient in a drug for treating hair loss, the concentration of each amino acid in the composition shall not exceed the maximum concentration permitted by the National Cosmetic Safety Network.

[0017] As a preferred embodiment of the application of the amino acid composition for treating hair loss described in this invention in the preparation of a medicament for treating hair loss, wherein the dosage form of the medicament includes a topical application, a spray, an ointment, or a liniment.

[0018] Beneficial effects of this invention:

[0019] 1. This invention employs a two-component design of "targeted core intervention components + auxiliary strengthening synergistic components." On one hand, the targeted core intervention components directly replenish key amino acid precursors for keratin synthesis (keratin is the main structural component of hair), providing a material basis for hair structure formation. On the other hand, by activating dermal papilla cells (DPC), it achieves the dual effects of "hair follicle function repair + active hair regeneration," surpassing existing drugs that only focus on delaying degeneration and truly improving the metabolic state of hair follicles.

[0020] 2. All components of this invention are naturally occurring or essential amino acids in the human body, without any exogenous chemical drug components. This avoids the adverse reactions present in existing hair loss treatments from the root cause. At the same time, its effects do not depend on inhibiting androgens or regulating immunity, and it has no gender or hair loss type restrictions. It can be applied to different types of hair loss and has safety and universality. Attached Figure Description

[0021] To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the following description of the embodiments will be briefly introduced. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0022] Figure 1 A comparative graph showing the effects of different drug application formulations on promoting hair regeneration in mice. Detailed Implementation

[0023] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, the specific embodiments of the present invention will be described in detail below with reference to the examples in the specification.

[0024] Many specific details are set forth in the following description in order to provide a full understanding of the invention. However, the invention may also be practiced in other ways different from those described herein, and those skilled in the art can make similar extensions without departing from the spirit of the invention. Therefore, the invention is not limited to the specific embodiments disclosed below.

[0025] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The phrase "in one embodiment" appearing in different places in this specification does not necessarily refer to the same embodiment, nor is it a single or selective embodiment that is mutually exclusive with other embodiments.

[0026] Unless otherwise specified, all raw materials used in this invention are commercially available in the field.

[0027] Example 1: This example provides an amino acid composition formulation for treating hair loss. The amino acid composition formulation consists of a targeted core intervention component and auxiliary strengthening and synergistic components. Specifically, based on the mass fractions of each component:

[0028] Targeted core intervention components: 33 parts arginine (Arg), 99 parts lysine (Lys), 105 parts glutamic acid (Glu), 26 parts cysteine ​​(Cys), and 47 parts leucine (Leu).

[0029] Auxiliary and synergistic components: 31 parts tyrosine (Tyr), 30 parts glycine (Gly), 23 parts glutamine (Gln), 28 parts serine (Ser), 15 parts alanine (Ala), 9 parts aspartic acid (Asn), and 25 parts phenylalanine (Phe).

[0030] The targeted core intervention component and the auxiliary strengthening and synergistic component are mixed at a mass ratio of 7:3 to obtain the amino acid composition formula for treating hair loss in this embodiment.

[0031] Comparative Example 1: This comparative example provides an amino acid composition formulation with the same types of amino acids as Example 1, but in different proportions. Specifically,

[0032] Targeted core intervention components: 30 parts arginine (Arg), 75 parts lysine (Lys), 70 parts glutamic acid (Glu), 20 parts cysteine ​​(Cys), and 35 parts leucine (Leu);

[0033] Auxiliary and synergistic components: 25 parts tyrosine (Tyr), 22 parts glycine (Gly), 20 parts glutamine (Gln), 25 parts serine (Ser), 10 parts alanine (Ala), 5 parts aspartic acid (Asn), and 20 parts phenylalanine (Phe).

[0034] The targeted core intervention component and the auxiliary strengthening and synergistic component are mixed at a mass ratio of 7:3 to obtain the amino acid composition formula for treating hair loss in this comparative proportion.

[0035] The amino acid compositions of Example 1 and Comparative Example 1 were formulated into liquid coatings, specifically:

[0036] Add deionized water, ethanol, and 1,2-propanediol to the main container. Add the amino acid composition formula (1g per part) while stirring. Slowly heat to 40°C and stir until completely dissolved and clear. Make up to volume and adjust the pH of the solution to 6 (weakly acidic). Filter to sterilize and dispense to obtain the amino acid composition coating for treating hair loss. Store at 4°C.

[0037] The following methods were used to verify the effects of different formulations of amino acid composition coatings on promoting hair regeneration:

[0038] The experimental animals were male C57 mice, weighing 18-22g;

[0039] The laboratory animal room is maintained at a temperature of 25±1℃ and a relative humidity of 50±5%. It is ventilated by exhaust fans and has natural light for 12 hours per day. The animals are housed in cages, with 5 animals per cage. The cages are cleaned once a day.

[0040] Mice were pre-fed for 7 days, and the hair on their backs was shaved off with a shaver. Then, Veet hair removal cream was used to remove the hair on their backs. Dihydrotestosterone (DHT) (10 mg / mL) was injected subcutaneously at multiple points once a day to establish an androgenic alopecia model.

[0041] The above-mentioned ointment and commercially available minoxidil (MINO) hair regrowth promoter were evenly applied to the hairless area on the back of mice, and the medication was applied once a day (0.2 mL / mouse). The hair regrowth effect of each group of mice was observed. The results of hair weight and length are expressed as mean ± standard deviation, as shown in Table 1.

[0042] Table 1 Comparison of the effects of different coatings on promoting hair growth

[0043]

[0044] Table 1 shows the average hair growth effect in each group of mice. Figure 1 A comparative graph showing the effects of different groups of drug application on promoting hair regeneration in mice. In the graph, 'd' represents the number of days. (From Table 1 and...) Figure 1 It can be seen that the coating made from the amino acid composition of Example 1 of the present invention can not only promote normal hair growth, but also significantly combat DHT-induced hair loss. It is superior to the commonly used clinical drug minoxidil in terms of hair regeneration amount (weight) and maturity (length), and has excellent overall hair growth effect. Although the amino acid composition of Comparative Example 1 has a certain hair growth effect, its effect is still lower than that of the commonly used clinical drug minoxidil.

[0045] Example 2, Targeted core intervention components: 50 parts arginine (Arg), 155 parts lysine (Lys), 120 parts glutamic acid (Glu), 40 parts cysteine ​​(Cys), 60 parts leucine (Leu).

[0046] Synergistic and enhancing components: 45 parts tyrosine (Tyr), 40 parts glycine (Gly), 40 parts glutamine (Gln), 35 parts serine (Ser), 25 parts alanine (Ala), 20 parts aspartic acid (Asn), and 35 parts phenylalanine (Phe).

[0047] The targeted core intervention component and the auxiliary strengthening and synergistic component are mixed at a mass ratio of 7:3 to obtain the amino acid composition formula for treating hair loss in this embodiment.

[0048] Example 3, Targeted core intervention components: 40 parts arginine (Arg), 120 parts lysine (Lys), 110 parts glutamic acid (Glu), 30 parts cysteine ​​(Cys), 50 parts leucine (Leu).

[0049] Auxiliary and synergistic components: 35 parts tyrosine (Tyr), 34 parts glycine (Gly), 30 parts glutamine (Gln), 30 parts serine (Ser), 20 parts alanine (Ala), 15 parts aspartic acid (Asn), and 31 parts phenylalanine (Phe).

[0050] The targeted core intervention component and the auxiliary strengthening and synergistic component are mixed at a mass ratio of 7:3 to obtain the amino acid composition formula for treating hair loss in this embodiment.

[0051] The formulations of Examples 2 and 3 were prepared into liquid coatings according to the method of Example 1, and the effects of different formulations of amino acid composition coatings on promoting hair regeneration were verified. The results were all superior to the commonly used clinical drug minoxidil.

[0052] Comparative Example 2 differs from Example 1 in that it omits the auxiliary strengthening and synergistic components and uses only the core intervention component as the amino acid composition formulation for treating hair loss in this comparative example.

[0053] Comparative Example 3 differs from Example 1 in that cysteine ​​in the core intervention component is omitted, glycine in the synergistic enhancement component is omitted, and the amounts of other components are adaptively adjusted to keep the total amount of the formula unchanged. The specific formula is as follows:

[0054] Targeted core intervention components: 39 parts arginine (Arg), 106 parts lysine (Lys), 112 parts glutamic acid (Glu), and 53 parts leucine (Leu).

[0055] Synergistic and enhancing components: 36 parts tyrosine (Tyr), 28 parts glutamine (Gln), 33 parts serine (Ser), 20 parts alanine (Ala), 16 parts aspartic acid (Asn), and 30 parts phenylalanine (Phe).

[0056] The targeted core intervention component and the auxiliary strengthening and synergistic component are mixed at a mass ratio of 7:3 to obtain the amino acid composition formula for treating hair loss in this comparative proportion.

[0057] Comparative Example 4 differs from Example 1 in that 10 parts of threonine (Thr), 10 parts of histidine (His), and 10 parts of proline (Pro) are added to the auxiliary strengthening and synergistic components, while the rest of the formulation is the same as in Example 1, thus obtaining the amino acid composition formulation for treating hair loss in this comparative example.

[0058] Since DPC cells (dermal papilla cells) are the "core regulatory cells" of hair follicle growth, the survival / proliferation status of DPC cells detected by the MTT assay can reflect the effect of each formulation on promoting hair growth. DPC cells in the logarithmic growth phase were used at a concentration of 5 × 10⁻⁶ cells per ml. 4 Cells were plated at different concentrations, with 100 μL of cell suspension added to each well in a 96-well plate. The plates were then incubated at 37°C for 24 h in a sterile cell culture incubator. The culture medium was changed, and the amino acid composition formulations of Example 1 and Comparative Examples 2-4 were added (one part of each formulation was calculated based on an addition of 1 μg / ml of culture medium). The plates were then incubated at 37°C with 5% CO2 for 24 h in a sterile cell culture incubator and detected by MTT assay. All experiments were repeated three times. The results are expressed as mean ± standard deviation and are shown in Table 2.

[0059] Table 2 Comparison of DPC cell survival rates under different amino acid compositions

[0060]

[0061] As shown in Table 2, the two-component structure and specific amino acid selection of the formulation of this invention are key to maximizing the effect. The auxiliary strengthening and synergistic component and the targeted core intervention component in Comparative Example 1 have a key synergistic effect, and omitting them will significantly weaken the effect. The thiol group (-SH) in cysteine ​​is the core of the keratin disulfide bond, which can maintain the stability of hair structure. Glycine is an important component of keratin. Both are key amino acids for hair follicle growth and hair synthesis. Their absence will lead to a significant decrease in the function of the formulation. The introduction of other amino acids in Comparative Example 3 resulted in a decrease in the survival / proliferation effect of DPC cells. This is because there is a synergistic effect between the amino acids in the formulation of this invention. Adding other amino acids will not only fail to improve the effect, but may also lead to a slight decrease in the effect due to slight interference between components or concentration imbalance, while increasing production costs.

[0062] Comparative Example 5 differs from Example 1 in that lysine in the core intervention component is replaced with threonine, while the rest of the formulation is the same as in Example 1, resulting in the amino acid composition formulation for treating hair loss in this comparative example.

[0063] Comparative Example 6 differs from Example 1 in that cysteine ​​in the core intervention component is replaced with proline, while the rest of the formulation is the same as in Example 1, resulting in the amino acid composition formulation for treating hair loss in this comparative example.

[0064] Comparative Example 7 differs from Example 1 in that tyrosine in the auxiliary strengthening and synergistic component is replaced with histidine, while the rest of the formulation is the same as in Example 1, resulting in the amino acid composition formulation for treating hair loss in this comparative example.

[0065] The effects of the amino acid composition formulations of Comparative Examples 5 to 7 on the survival / proliferation status of DPC cells were determined and compared with Example 1. The results are shown in Table 3.

[0066] Table 3 Comparison of DPC cell survival rates under specific amino acid composition substitution conditions

[0067]

[0068] In this invention, lysine, cysteine, and tyrosine play core roles in nutrient transport, structural stability and cell protection, as well as signal regulation. They work synergistically and are irreplaceable, making them key components to ensure the effectiveness of the formula. Replacing them with other amino acids significantly reduces the hair growth promotion effect.

[0069] Comparative Example 8 differs from Example 1 in that the mass ratio of the targeted core intervention component to the auxiliary strengthening synergistic component is adjusted to 6:4, while the rest of the formulation is the same as in Example 1, thus obtaining the amino acid composition formulation for treating hair loss in this comparative example.

[0070] Comparative Example 9 differs from Example 1 in that the mass ratio of the targeted core intervention component to the auxiliary strengthening synergistic component is adjusted to 8:2, while the rest of the formulation is the same as in Example 1, thus obtaining the amino acid composition formulation for treating hair loss in this comparative example.

[0071] Comparative Example 10 differs from Example 1 in that the mass ratio of the targeted core intervention component to the auxiliary strengthening synergistic component is adjusted to 9:1, while the rest of the formulation is the same as in Example 1, thus obtaining the amino acid composition formulation for treating hair loss in this comparative example.

[0072] The effects of the amino acid composition formulations of Comparative Examples 8 to 10 on the survival / proliferation status of DPC cells were determined and compared with Example 1. The results are shown in Table 4.

[0073] Table 4 Comparison of DPC cell survival rates under different functional amino acid composition ratios

[0074]

[0075] As shown in Table 4, when the mass ratio of the core intervention component to the auxiliary strengthening and synergistic component is 7-8:2-3, the balance between core function and auxiliary synergy is optimal, and the survival rate of DPC cells is the highest. The core component is the main functional carrier for activating DPC cells and supplementing keratin precursors. Insufficient proportion leads to a weakened targeted intervention effect. Even if the auxiliary component is increased, it cannot make up for the lack of core function. The auxiliary component plays a role in synergistically strengthening the core function (such as glycine assisting keratin synthesis and glutamine maintaining DPC cell metabolism). If the proportion is too low, the synergistic effect will be weakened, and the function of the core component cannot be fully exerted.

[0076] Comparative Example 11 differs from Example 1 in that the amounts of arginine and lysine in the targeted core intervention components are adjusted to 40 parts and 80 parts respectively, with a mass ratio of 1:2. The rest of the formulation is the same as in Example 1, thus obtaining the amino acid composition formulation for treating hair loss in this comparative example.

[0077] Comparative Example 12 differs from Example 1 in that the amounts of arginine and lysine in the targeted core intervention component are adjusted to 30 parts and 120 parts, respectively, with a mass ratio of 1:4. The rest of the formulation is the same as in Example 1, thus obtaining the amino acid composition formulation for treating hair loss in this comparative example.

[0078] The effects of the amino acid composition formulations of Comparative Examples 9 to 10 on the survival / proliferation status of DPC cells were determined and compared with Example 1. The results are shown in Table 5.

[0079] Table 5 Comparison of DPC cell survival rates under different amounts and ratios of arginine and lysine.

[0080]

[0081] As shown in Table 5, the dosage and ratio of arginine and lysine in the core intervention components have a significant impact on the technical effect. Arginine can promote the production of nitric oxide (NO), which can dilate capillaries around hair follicles and improve local blood supply. Lysine can enhance the uptake and transport of nutrients such as amino acids and glucose by hair follicle cells. When the two are in a ratio of 3:8~10, the speed and efficiency of blood supply improvement and nutrient transport are highly matched, achieving synergistic optimization of "oxygen supply + energy supply" and maximizing the activation of DPC cells.

[0082] In summary, this invention employs a two-component design of "targeted core intervention components + auxiliary strengthening synergistic components." On one hand, the targeted core intervention components directly replenish key amino acid precursors for keratin synthesis (keratin is the main structural component of hair), providing a material basis for hair structure formation. On the other hand, by activating dermal papilla cells (DPCs), it achieves a dual effect of "hair follicle function repair + active hair regeneration," surpassing existing drugs that only focus on delaying degeneration and truly improving the metabolic state of hair follicles.

[0083] All components of this invention are naturally occurring or essential amino acids in the human body, without any exogenous chemical drug components. This avoids the adverse reactions present in existing hair loss treatments from the root cause. At the same time, its effects do not depend on inhibiting androgens or regulating immunity, and it has no gender or hair loss type restrictions. It can be applied to different types of hair loss and has both safety and universality.

[0084] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all such modifications or substitutions should be covered within the scope of the claims of the present invention.

Claims

1. An amino acid composition for treating hair loss, characterized in that: The amino acid composition comprises a targeted core intervention component and an auxiliary strengthening and synergistic component in a mass ratio of 7-8:2-3, wherein, by mass parts, The targeted core intervention component consists of 30-50 parts arginine, 90-155 parts lysine, 100-120 parts glutamic acid, 25-40 parts cysteine, and 45-60 parts leucine, wherein the mass ratio of arginine to lysine is 3:8-10. The auxiliary strengthening and synergistic component consists of 30-45 parts tyrosine, 30-40 parts glycine, 20-40 parts glutamine, 28-35 parts serine, 15-25 parts alanine, 5-20 parts aspartic acid, and 25-35 parts phenylalanine.

2. The amino acid composition for treating hair loss as described in claim 1, characterized in that: The targeted core intervention component consists of 30-40 parts arginine, 90-120 parts lysine, 100-110 parts glutamic acid, 25-30 parts cysteine, and 45-50 parts leucine.

3. The amino acid composition for treating hair loss as described in claim 2, characterized in that: The auxiliary strengthening and synergistic component consists of 30-35 parts tyrosine, 30-34 parts glycine, 20-30 parts glutamine, 28-35 parts serine, 15-25 parts alanine, 5-20 parts aspartic acid, and 25-31 parts phenylalanine.

4. The use of the amino acid composition for treating hair loss as described in any one of claims 1 to 3 in the preparation of a medicament for treating hair loss.

5. The use of the amino acid composition for treating hair loss as described in claim 4 in the preparation of a medicament for treating hair loss, characterized in that: The active ingredient is an amino acid composition for treating hair loss as described in any one of claims 1 to 3, and it also includes pharmaceutically acceptable adjuvants.

6. The use of the amino acid composition for treating hair loss as described in claim 5 in the preparation of a medicament for treating hair loss, characterized in that: The dosage forms of the drug include ointments, sprays, creams, and liniments.

Images